151 related articles for article (PubMed ID: 11766742)
1. Treatment for complex atypical hyperplasia of the endometrium.
Jobo T; Kawaguchi M; Imai M; Kuramoto H
Eur J Gynaecol Oncol; 2001; 22(5):365-8. PubMed ID: 11766742
[TBL] [Abstract][Full Text] [Related]
2. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome.
Kaku T; Yoshikawa H; Tsuda H; Sakamoto A; Fukunaga M; Kuwabara Y; Hataeg M; Kodama S; Kuzuya K; Sato S; Nishimura T; Hiura M; Nakano H; Iwasaka T; Miyazaki K; Kamura T
Cancer Lett; 2001 Jun; 167(1):39-48. PubMed ID: 11323097
[TBL] [Abstract][Full Text] [Related]
3. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
[TBL] [Abstract][Full Text] [Related]
4. Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study.
Emarh M
Arch Gynecol Obstet; 2015 Dec; 292(6):1339-43. PubMed ID: 26015309
[TBL] [Abstract][Full Text] [Related]
5. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
[TBL] [Abstract][Full Text] [Related]
6. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer.
Tamauchi S; Kajiyama H; Utsumi F; Suzuki S; Niimi K; Sakata J; Mizuno M; Shibata K; Kikkawa F
J Obstet Gynaecol Res; 2018 Jan; 44(1):151-156. PubMed ID: 29121428
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
9. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations.
Imai M; Jobo T; Sato R; Kawaguchi M; Kuramoto H
Eur J Gynaecol Oncol; 2001; 22(3):217-20. PubMed ID: 11501776
[TBL] [Abstract][Full Text] [Related]
10. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium.
Minaguchi T; Nakagawa S; Takazawa Y; Nei T; Horie K; Fujiwara T; Osuga Y; Yasugi T; Kugu K; Yano T; Yoshikawa H; Taketani Y
Cancer Lett; 2007 Apr; 248(1):112-22. PubMed ID: 16919866
[TBL] [Abstract][Full Text] [Related]
11. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia.
Inoue O; Hamatani T; Susumu N; Yamagami W; Ogawa S; Takemoto T; Hirasawa A; Banno K; Kuji N; Tanaka M; Aoki D
Reprod Biol Endocrinol; 2016 Jan; 14():2. PubMed ID: 26769300
[TBL] [Abstract][Full Text] [Related]
13. Comparing letrozole with medroxyprogesterone acetate (MPA) as hormonal therapy for simple endometrial hyperplasia without atypia in adult and middle-aged women.
Tabatabaie A; Karimi Zarchi M; Dehghani-Tafti M; Miratashi-Yazdi A; Teimoori S; Dehghani A
Eur J Gynaecol Oncol; 2013; 34(6):552-5. PubMed ID: 24601050
[TBL] [Abstract][Full Text] [Related]
14. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
15. Oncologic, fertility, and obstetric outcomes with MPA therapy in women with endometrial cancer and atypical endometrial hyperplasia.
Takeda A; Yamamoto Y; Tamura K; Aoki H; Noguchi H; Minato S; Kamada S; Arakaki R; Kaji T; Iwasa T
J Obstet Gynaecol Res; 2024 Apr; 50(4):633-638. PubMed ID: 38154145
[TBL] [Abstract][Full Text] [Related]
16. Failure of down-regulation of estrogen receptors and progesterone receptors after medroxyprogesterone acetate administration for endometrial hyperplasias.
Masuzawa H; Badokhon NH; Nakayama K; Konishi I; Nikaido T; Fujii S
Cancer; 1994 Oct; 74(8):2321-8. PubMed ID: 7922983
[TBL] [Abstract][Full Text] [Related]
17. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Mitsuhashi A; Kawasaki Y; Hori M; Fujiwara T; Hanaoka H; Shozu M
BMJ Open; 2020 Feb; 10(2):e035416. PubMed ID: 32114477
[TBL] [Abstract][Full Text] [Related]
18. Protecting the endometrium. Opposing the hyperplasia/malignancy potential of ERT.
Gibbons WE; Thorneycroft IH
J Reprod Med; 1999 Feb; 44(2 Suppl):203-8. PubMed ID: 11392033
[TBL] [Abstract][Full Text] [Related]
19. Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy.
Figueroa-Casas PR; Ettinger B; Delgado E; Javkin A; Vieder C
Menopause; 2001; 8(6):420-3. PubMed ID: 11723414
[TBL] [Abstract][Full Text] [Related]
20. Organ preserving method in the management of atypical endometrial hyperplasia.
Kobiashvili H; Charkviani L; Charkviani T
Eur J Gynaecol Oncol; 2001; 22(4):297-9. PubMed ID: 11695813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
